{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:56:20Z","timestamp":1793998580182,"version":"4.8.0"},"reference-count":184,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41574-023-00809-4","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T11:04:13Z","timestamp":1681383853000},"page":"336-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["The role of ChREBP in carbohydrate sensing and NAFLD development"],"prefix":"10.1038","volume":"19","author":[{"given":"Marion","family":"R\u00e9gnier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tha\u00efs","family":"Carbinatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Parlati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadila","family":"Benhamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Postic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"809_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"809_CR2","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1172\/JCI23621","volume":"115","author":"KL Donnelly","year":"2005","unstructured":"Donnelly, K. L. et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343\u20131351 (2005).","journal-title":"J. Clin. Invest."},{"key":"809_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba, R., Friedman, S. L. & Shulman, G. I. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 184, 2537\u20132564 (2021).","journal-title":"Cell"},{"key":"809_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/nrendo.2017.56","volume":"13","author":"RCR Meex","year":"2017","unstructured":"Meex, R. C. R. & Watt, M. J. Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 13, 509\u2013520 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"809_CR5","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2337\/db06-1491","volume":"56","author":"PD Cani","year":"2007","unstructured":"Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761\u20131772 (2007).","journal-title":"Diabetes"},{"key":"809_CR6","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","volume":"65","author":"A Montagner","year":"2016","unstructured":"Montagner, A. et al. Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD. Gut 65, 1202\u20131214 (2016).","journal-title":"Gut"},{"key":"809_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mce.2017.07.035","volume":"471","author":"M R\u00e9gnier","year":"2018","unstructured":"R\u00e9gnier, M. et al. Insights into the role of hepatocyte PPAR\u03b1 activity in response to fasting. Mol. Cell Endocrinol. 471, 75\u201388 (2018).","journal-title":"Mol. Cell Endocrinol."},{"key":"809_CR8","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.4254\/wjh.v7.i8.1012","volume":"7","author":"V Souza-Mello","year":"2015","unstructured":"Souza-Mello, V. Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease. World J. Hepatol. 7, 1012\u20131019 (2015).","journal-title":"World J. Hepatol."},{"key":"809_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi, K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 142, 711\u2013725.e6 (2012).","journal-title":"Gastroenterology"},{"key":"809_CR10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio, R. E., Chen, E. R. & Lazar, M. A. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 20, 573\u2013591 (2014).","journal-title":"Cell Metab."},{"key":"809_CR11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1042\/CS20110373","volume":"123","author":"JC Fraulob","year":"2012","unstructured":"Fraulob, J. C., Souza-Mello, V., Aguila, M. B. & Mandarim-de-Lacerda, C. A. Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet. Clin. Sci. 123, 259\u2013270 (2012).","journal-title":"Clin. Sci."},{"key":"809_CR12","doi-asserted-by":"publisher","first-page":"21991","DOI":"10.1074\/jbc.270.37.21991","volume":"270","author":"HM Shih","year":"1995","unstructured":"Shih, H. M., Liu, Z. & Towle, H. C. Two CACGTG motifs with proper spacing dictate the carbohydrate regulation of hepatic gene transcription. J. Biol. Chem. 270, 21991\u201321997 (1995).","journal-title":"J. Biol. Chem."},{"key":"809_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1146\/annurev.nutr.17.1.325","volume":"17","author":"J Girard","year":"1997","unstructured":"Girard, J., Ferr\u00e9, P. & Foufelle, F. Mechanisms by which carbohydrates regulate expression of genes for glycolytic and lipogenic enzymes. Annu. Rev. Nutr. 17, 325\u2013352 (1997).","journal-title":"Annu. Rev. Nutr."},{"key":"809_CR14","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1146\/annurev.nutr.17.1.405","volume":"17","author":"HC Towle","year":"1997","unstructured":"Towle, H. C., Kaytor, E. N. & Shih, H. M. Regulation of the expression of lipogenic enzyme genes by carbohydrate. Annu. Rev. Nutr. 17, 405\u2013433 (1997).","journal-title":"Annu. Rev. Nutr."},{"key":"809_CR15","doi-asserted-by":"publisher","first-page":"28721","DOI":"10.1074\/jbc.M601576200","volume":"281","author":"L Ma","year":"2006","unstructured":"Ma, L., Robinson, L. N. & Towle, H. C. ChREBP*Mlx is the principal mediator of glucose-induced gene expression in the liver. J. Biol. Chem. 281, 28721\u201328730 (2006).","journal-title":"J. Biol. Chem."},{"key":"809_CR16","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1210\/en.2014-1666","volume":"156","author":"N Poungvarin","year":"2015","unstructured":"Poungvarin, N. et al. Genome-wide analysis of ChREBP binding sites on male mouse liver and white adipose chromatin. Endocrinology 156, 1982\u20131994 (2015).","journal-title":"Endocrinology"},{"key":"809_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022544","volume":"6","author":"Y-S Jeong","year":"2011","unstructured":"Jeong, Y.-S. et al. Integrated expression profiling and genome-wide analysis of ChREBP targets reveals the dual role for ChREBP in glucose-regulated gene expression. PLoS ONE 6, e22544 (2011).","journal-title":"PLoS ONE"},{"key":"809_CR18","doi-asserted-by":"publisher","first-page":"7281","DOI":"10.1073\/pnas.0401516101","volume":"101","author":"K Iizuka","year":"2004","unstructured":"Iizuka, K., Bruick, R. K., Liang, G., Horton, J. D. & Uyeda, K. Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis. Proc. Natl Acad. Sci. USA 101, 7281\u20137286 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR19","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nrgastro.2010.41","volume":"7","author":"JS Lim","year":"2010","unstructured":"Lim, J. S., Mietus-Snyder, M., Valente, A., Schwarz, J.-M. & Lustig, R. H. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 7, 251\u2013264 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"809_CR20","doi-asserted-by":"publisher","first-page":"32746","DOI":"10.1074\/jbc.M201635200","volume":"277","author":"H Wang","year":"2002","unstructured":"Wang, H. & Wollheim, C. B. ChREBP rather than USF2 regulates glucose stimulation of endogenous L-pyruvate kinase expression in insulin-secreting cells. J. Biol. Chem. 277, 32746\u201332752 (2002).","journal-title":"J. Biol. Chem."},{"key":"809_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1530\/JOE-20-0442","volume":"248","author":"K Takao","year":"2021","unstructured":"Takao, K. et al. Effects of ChREBP deficiency on adrenal lipogenesis and steroidogenesis. J. Endocrinol. 248, 317\u2013324 (2021).","journal-title":"J. Endocrinol."},{"key":"809_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.metabol.2017.01.033","volume":"70","author":"P Richards","year":"2017","unstructured":"Richards, P. et al. MondoA\/ChREBP: The usual suspects of transcriptional glucose sensing; Implication in pathophysiology. Metabolism 70, 133\u2013151 (2017).","journal-title":"Metabolism"},{"key":"809_CR23","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1172\/JCI87382","volume":"126","author":"B Ahn","year":"2016","unstructured":"Ahn, B. et al. MondoA coordinately regulates skeletal myocyte lipid homeostasis and insulin signaling. J. Clin. Invest. 126, 3567\u20133579 (2016).","journal-title":"J. Clin. Invest."},{"key":"809_CR24","doi-asserted-by":"publisher","first-page":"20543","DOI":"10.1016\/S0021-9258(19)36717-1","volume":"267","author":"F Foufelle","year":"1992","unstructured":"Foufelle, F. et al. Glucose stimulation of lipogenic enzyme gene expression in cultured white adipose tissue. A role for glucose 6-phosphate. J. Biol. Chem. 267, 20543\u201320546 (1992).","journal-title":"J. Biol. Chem."},{"key":"809_CR25","doi-asserted-by":"publisher","first-page":"9116","DOI":"10.1073\/pnas.161284298","volume":"98","author":"H Yamashita","year":"2001","unstructured":"Yamashita, H. et al. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. Proc. Natl Acad. Sci. USA 98, 9116\u20139121 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.bbrc.2009.09.109","volume":"390","author":"H-Y Koo","year":"2009","unstructured":"Koo, H.-Y., Miyashita, M., Cho, B. H. S. & Nakamura, M. T. Replacing dietary glucose with fructose increases ChREBP activity and SREBP-1 protein in rat liver nucleus. Biochem. Biophys. Res. Commun. 390, 285\u2013289 (2009).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"809_CR27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1042\/BJ20111280","volume":"443","author":"C Arden","year":"2012","unstructured":"Arden, C. et al. Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes. Biochem. J. 443, 111\u2013123 (2012).","journal-title":"Biochem. J."},{"key":"809_CR28","doi-asserted-by":"publisher","first-page":"40732","DOI":"10.1074\/jbc.M112.399899","volume":"287","author":"MA Lanaspa","year":"2012","unstructured":"Lanaspa, M. A. et al. Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and -independent fatty liver. J. Biol. Chem. 287, 40732\u201340744 (2012).","journal-title":"J. Biol. Chem."},{"key":"809_CR29","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.2337\/db05-0822","volume":"55","author":"MV Li","year":"2006","unstructured":"Li, M. V., Chang, B., Imamura, M., Poungvarin, N. & Chan, L. Glucose-dependent transcriptional regulation by an evolutionarily conserved glucose-sensing module. Diabetes 55, 1179\u20131189 (2006).","journal-title":"Diabetes"},{"key":"809_CR30","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.1073\/pnas.0730817100","volume":"100","author":"T Kabashima","year":"2003","unstructured":"Kabashima, T., Kawaguchi, T., Wadzinski, B. E. & Uyeda, K. Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver. Proc. Natl Acad. Sci. USA 100, 5107\u20135112 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR31","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jhep.2011.07.019","volume":"56","author":"R Dentin","year":"2012","unstructured":"Dentin, R. et al. Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver. J. Hepatol. 56, 199\u2013209 (2012).","journal-title":"J. Hepatol."},{"key":"809_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0034803","volume":"7","author":"LG McFerrin","year":"2012","unstructured":"McFerrin, L. G. & Atchley, W. R. A novel N-terminal domain may dictate the glucose response of Mondo proteins. PLoS ONE 7, e34803 (2012).","journal-title":"PLoS ONE"},{"key":"809_CR33","doi-asserted-by":"publisher","first-page":"13710","DOI":"10.1073\/pnas.231370798","volume":"98","author":"T Kawaguchi","year":"2001","unstructured":"Kawaguchi, T., Takenoshita, M., Kabashima, T. & Uyeda, K. Glucose and cAMP regulate the L-type pyruvate kinase gene by phosphorylation\/dephosphorylation of the carbohydrate response element binding protein. Proc. Natl Acad. Sci. USA 98, 13710\u201313715 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR34","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1530\/JOE-11-0480","volume":"213","author":"I Leclerc","year":"2012","unstructured":"Leclerc, I., Rutter, G. A., Meur, G. & Noordeen, N. Roles of Ca2+ ions in the control of ChREBP nuclear translocation. J. Endocrinol. 213, 115\u2013122 (2012).","journal-title":"J. Endocrinol."},{"key":"809_CR35","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1002\/1873-3468.13538","volume":"593","author":"P Vineeth Daniel","year":"2019","unstructured":"Vineeth Daniel, P. et al. Chronic exposure to Pb2+ perturbs ChREBP transactivation and coerces hepatic dyslipidemia. FEBS Lett. 593, 3084\u20133097 (2019).","journal-title":"FEBS Lett."},{"key":"809_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cmet.2017.07.004","volume":"26","author":"A Abdul-Wahed","year":"2017","unstructured":"Abdul-Wahed, A., Guilmeau, S. & Postic, C. Sweet sixteenth for ChREBP: established roles and future goals. Cell Metab. 26, 324\u2013341 (2017).","journal-title":"Cell Metab."},{"key":"809_CR37","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1242\/jcs.053678","volume":"123","author":"Q Zeidan","year":"2010","unstructured":"Zeidan, Q. & Hart, G. W. The intersections between O-GlcNAcylation and phosphorylation: implications for multiple signaling pathways. J. Cell Sci. 123, 13\u201322 (2010).","journal-title":"J. Cell Sci."},{"key":"809_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1631\/jzus.B1900150","volume":"20","author":"H Nie","year":"2019","unstructured":"Nie, H. & Yi, W. O-GlcNAcylation, a sweet link to the pathology of diseases. J. Zhejiang Univ. Sci. B 20, 437\u2013448 (2019).","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"809_CR39","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2337\/db10-0452","volume":"60","author":"C Guinez","year":"2011","unstructured":"Guinez, C. et al. O-GlcNAcylation increases ChREBP protein content and transcriptional activity in the liver. Diabetes 60, 1399\u20131413 (2011).","journal-title":"Diabetes"},{"key":"809_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.molcel.2019.05.019","volume":"75","author":"EA Lane","year":"2019","unstructured":"Lane, E. A. et al. HCF-1 regulates de novo lipogenesis through a nutrient-sensitive complex with ChREBP. Mol. Cell 75, 357\u2013371.e7 (2019).","journal-title":"Mol. Cell"},{"key":"809_CR41","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature10986","volume":"484","author":"MA Herman","year":"2012","unstructured":"Herman, M. A. et al. A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism. Nature 484, 333\u2013338 (2012).","journal-title":"Nature"},{"key":"809_CR42","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1172\/JCI29027","volume":"116","author":"MA Herman","year":"2006","unstructured":"Herman, M. A. & Kahn, B. B. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J. Clin. Invest. 116, 1767\u20131775 (2006).","journal-title":"J. Clin. Invest."},{"key":"809_CR43","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.2337\/db15-0239","volume":"64","author":"P Zhang","year":"2015","unstructured":"Zhang, P. et al. Induction of the ChREBP\u03b2 isoform is essential for glucose-stimulated \u03b2-cell proliferation. Diabetes 64, 4158\u20134170 (2015).","journal-title":"Diabetes"},{"key":"809_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11365","volume":"7","author":"Y Tang","year":"2016","unstructured":"Tang, Y. et al. Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism. Nat. Commun. 7, 11365 (2016).","journal-title":"Nat. Commun."},{"key":"809_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32162-x","volume":"13","author":"LS Katz","year":"2022","unstructured":"Katz, L. S. et al. Maladaptive positive feedback production of ChREBP\u03b2 underlies glucotoxic \u03b2-cell failure. Nat. Commun. 13, 4423 (2022).","journal-title":"Nat. Commun."},{"key":"809_CR46","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1016\/j.molmet.2017.07.006","volume":"6","author":"T Jois","year":"2017","unstructured":"Jois, T. et al. Deletion of hepatic carbohydrate response element binding protein (ChREBP) impairs glucose homeostasis and hepatic insulin sensitivity in mice. Mol. Metab. 6, 1381\u20131394 (2017).","journal-title":"Mol. Metab."},{"key":"809_CR47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.96703","volume":"2","author":"M Kim","year":"2017","unstructured":"Kim, M. et al. Intestinal, but not hepatic, ChREBP is required for fructose tolerance. JCI Insight 2, e96703 (2017).","journal-title":"JCI Insight"},{"key":"809_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153431","volume":"7","author":"E Recazens","year":"2022","unstructured":"Recazens, E. et al. ChREBP\u03b2 is dispensable for the control of glucose homeostasis and energy balance. JCI Insight 7, e153431 (2022).","journal-title":"JCI Insight"},{"key":"809_CR49","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.tem.2016.06.005","volume":"27","author":"MA Herman","year":"2016","unstructured":"Herman, M. A. & Samuel, V. T. The sweet path to metabolic demise: fructose and lipid synthesis. Trends Endocrinol. Metab. 27, 719\u2013730 (2016).","journal-title":"Trends Endocrinol. Metab."},{"key":"809_CR50","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1172\/JCI81993","volume":"126","author":"M-S Kim","year":"2016","unstructured":"Kim, M.-S. et al. ChREBP regulates fructose-induced glucose production independently of insulin signaling. J. Clin. Invest. 126, 4372\u20134386 (2016).","journal-title":"J. Clin. Invest."},{"key":"809_CR51","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00125-012-2506-4","volume":"55","author":"N Poungvarin","year":"2012","unstructured":"Poungvarin, N. et al. Carbohydrate response element-binding protein (ChREBP) plays a pivotal role in beta cell glucotoxicity. Diabetologia 55, 1783\u20131796 (2012).","journal-title":"Diabetologia"},{"key":"809_CR52","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1016\/S0140-6736(10)60408-4","volume":"375","author":"VT Samuel","year":"2010","unstructured":"Samuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267\u20132277 (2010).","journal-title":"Lancet"},{"key":"809_CR53","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1053\/j.gastro.2018.06.031","volume":"155","author":"G Musso","year":"2018","unstructured":"Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Bioactive lipid species and metabolic pathways in progression and resolution of nonalcoholic steatohepatitis. Gastroenterology 155, 282\u2013302.e8 (2018).","journal-title":"Gastroenterology"},{"key":"809_CR54","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2337\/db06-0200","volume":"55","author":"R Dentin","year":"2006","unstructured":"Dentin, R. et al. Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob\/ob mice. Diabetes 55, 2159\u20132170 (2006).","journal-title":"Diabetes"},{"key":"809_CR55","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1172\/JCI41636","volume":"122","author":"F Benhamed","year":"2012","unstructured":"Benhamed, F. et al. The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans. J. Clin. Invest. 122, 2176\u20132194 (2012).","journal-title":"J. Clin. Invest."},{"key":"809_CR56","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cmet.2007.05.005","volume":"6","author":"M Monetti","year":"2007","unstructured":"Monetti, M. et al. Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver. Cell Metab. 6, 69\u201378 (2007).","journal-title":"Cell Metab."},{"key":"809_CR57","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.21655","volume":"45","author":"K Yamaguchi","year":"2007","unstructured":"Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366\u20131374 (2007).","journal-title":"Hepatology"},{"key":"809_CR58","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.30765","volume":"70","author":"NL Gluchowski","year":"2019","unstructured":"Gluchowski, N. L. et al. Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice. Hepatology 70, 1972\u20131985 (2019).","journal-title":"Hepatology"},{"key":"809_CR59","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.cmet.2011.02.011","volume":"13","author":"P Kulozik","year":"2011","unstructured":"Kulozik, P. et al. Hepatic deficiency in transcriptional cofactor TBL1 promotes liver steatosis and hypertriglyceridemia. Cell Metab. 13, 389\u2013400 (2011).","journal-title":"Cell Metab."},{"key":"809_CR60","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/egh.09.32","volume":"3","author":"N Alkhouri","year":"2009","unstructured":"Alkhouri, N., Dixon, L. J. & Feldstein, A. E. Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert. Rev. Gastroenterol. Hepatol. 3, 445\u2013451 (2009).","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"809_CR61","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.plipres.2012.10.004","volume":"52","author":"AK Leamy","year":"2013","unstructured":"Leamy, A. K., Egnatchik, R. A. & Young, J. D. Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease. Prog. Lipid Res. 52, 165\u2013174 (2013).","journal-title":"Prog. Lipid Res."},{"key":"809_CR62","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.tips.2020.12.001","volume":"42","author":"I Semova","year":"2021","unstructured":"Semova, I. & Biddinger, S. B. Triglycerides in nonalcoholic fatty liver disease: guilty until proven innocent. Trends Pharmacol. Sci. 42, 183\u2013190 (2021).","journal-title":"Trends Pharmacol. Sci."},{"key":"809_CR63","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/j.jhep.2016.01.002","volume":"64","author":"PK Luukkonen","year":"2016","unstructured":"Luukkonen, P. K. et al. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease. J. Hepatol. 64, 1167\u20131175 (2016).","journal-title":"J. Hepatol."},{"key":"809_CR64","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1053\/j.gastro.2012.03.003","volume":"142","author":"F Magkos","year":"2012","unstructured":"Magkos, F. et al. Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects. Gastroenterology 142, 1444\u20131446.e2 (2012).","journal-title":"Gastroenterology"},{"key":"809_CR65","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1172\/JCI44442","volume":"121","author":"EP Rhee","year":"2011","unstructured":"Rhee, E. P. et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J. Clin. Invest. 121, 1402\u20131411 (2011).","journal-title":"J. Clin. Invest."},{"key":"809_CR66","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/JCI25256","volume":"115","author":"R Dentin","year":"2005","unstructured":"Dentin, R. et al. Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation. J. Clin. Invest. 115, 2843\u20132854 (2005).","journal-title":"J. Clin. Invest."},{"key":"809_CR67","doi-asserted-by":"publisher","first-page":"E788","DOI":"10.1152\/ajpendo.00510.2006","volume":"292","author":"KB Pedersen","year":"2007","unstructured":"Pedersen, K. B. et al. The promoter for the gene encoding the catalytic subunit of rat glucose-6-phosphatase contains two distinct glucose-responsive regions. Am. J. Physiol. Endocrinol. Metab. 292, E788\u2013E801 (2007).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"809_CR68","doi-asserted-by":"publisher","first-page":"24559","DOI":"10.1074\/jbc.274.35.24559","volume":"274","author":"S Aiston","year":"1999","unstructured":"Aiston, S., Trinh, K. Y., Lange, A. J., Newgard, C. B. & Agius, L. Glucose-6-phosphatase overexpression lowers glucose 6-phosphate and inhibits glycogen synthesis and glycolysis in hepatocytes without affecting glucokinase translocation. Evidence against feedback inhibition of glucokinase. J. Biol. Chem. 274, 24559\u201324566 (1999).","journal-title":"J. Biol. Chem."},{"key":"809_CR69","doi-asserted-by":"publisher","first-page":"12854","DOI":"10.1074\/jbc.272.19.12854","volume":"272","author":"D Argaud","year":"1997","unstructured":"Argaud, D., Kirby, T. L., Newgard, C. B. & Lange, A. J. Stimulation of glucose-6-phosphatase gene expression by glucose and fructose-2,6-bisphosphate. J. Biol. Chem. 272, 12854\u201312861 (1997).","journal-title":"J. Biol. Chem."},{"key":"809_CR70","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/BJ20101225","volume":"432","author":"A Grefhorst","year":"2010","unstructured":"Grefhorst, A. et al. Carbohydrate-response-element-binding protein (ChREBP) and not the liver X receptor \u03b1 (LXR\u03b1) mediates elevated hepatic lipogenic gene expression in a mouse model of glycogen storage disease type 1. Biochem. J. 432, 249\u2013254 (2010).","journal-title":"Biochem. J."},{"key":"809_CR71","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.molmet.2014.05.005","volume":"3","author":"A Abdul-Wahed","year":"2014","unstructured":"Abdul-Wahed, A. et al. A link between hepatic glucose production and peripheral energy metabolism via hepatokines. Mol. Metab. 3, 531\u2013543 (2014).","journal-title":"Mol. Metab."},{"key":"809_CR72","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006819","volume":"13","author":"J-H Cho","year":"2017","unstructured":"Cho, J.-H. et al. Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia. PLoS Genet. 13, e1006819 (2017).","journal-title":"PLoS Genet."},{"key":"809_CR73","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/hep.31198","volume":"72","author":"Y Lei","year":"2020","unstructured":"Lei, Y. et al. Hepatic carbohydrate response element binding protein activation limits nonalcoholic fatty liver disease development in a mouse model for glycogen storage disease type 1a. Hepatology 72, 1638\u20131653 (2020).","journal-title":"Hepatology"},{"key":"809_CR74","doi-asserted-by":"publisher","first-page":"101108","DOI":"10.1016\/j.molmet.2020.101108","volume":"43","author":"F Rajas","year":"2021","unstructured":"Rajas, F. et al. The absence of hepatic glucose-6 phosphatase\/ChREBP couple is incompatible with survival in mice. Mol. Metab. 43, 101108 (2021).","journal-title":"Mol. Metab."},{"key":"809_CR75","doi-asserted-by":"publisher","first-page":"E102","DOI":"10.1152\/ajpendo.00326.2020","volume":"320","author":"L Vel\u00e1zquez-Villegas","year":"2021","unstructured":"Vel\u00e1zquez-Villegas, L. et al. ChREBP downregulates SNAT2 amino acid transporter expression through interactions with SMRT in response to a high-carbohydrate diet. Am. J. Physiol. Endocrinol. Metab. 320, E102\u2013E112 (2021).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"809_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1001485","volume":"11","author":"A Girousse","year":"2013","unstructured":"Girousse, A. et al. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol. 11, e1001485 (2013).","journal-title":"PLoS Biol."},{"key":"809_CR77","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s42255-018-0007-6","volume":"1","author":"P Morigny","year":"2019","unstructured":"Morigny, P. et al. Interaction between hormone-sensitive lipase and ChREBP in fat cells controls insulin sensitivity. Nat. Metab. 1, 133\u2013146 (2019).","journal-title":"Nat. Metab."},{"key":"809_CR78","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.celrep.2017.09.091","volume":"21","author":"A Vijayakumar","year":"2017","unstructured":"Vijayakumar, A. et al. Absence of carbohydrate response element binding protein in adipocytes causes systemic insulin resistance and impairs glucose transport. Cell Rep. 21, 1021\u20131035 (2017).","journal-title":"Cell Rep."},{"key":"809_CR79","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cell.2014.09.035","volume":"159","author":"MM Yore","year":"2014","unstructured":"Yore, M. M. et al. Discovery of a class of endogenous mammalian lipids with anti-diabetic and anti-inflammatory effects. Cell 159, 318\u2013332 (2014).","journal-title":"Cell"},{"key":"809_CR80","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1530\/JOE-19-0498","volume":"245","author":"C Wei","year":"2020","unstructured":"Wei, C. et al. ChREBP-\u03b2 regulates thermogenesis in brown adipose tissue. J. Endocrinol. 245, 343\u2013356 (2020).","journal-title":"J. Endocrinol."},{"key":"809_CR81","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s11010-021-04178-2","volume":"476","author":"H Sakiyama","year":"2021","unstructured":"Sakiyama, H. et al. A lack of ChREBP inhibits mitochondrial cristae formation in brown adipose tissue. Mol. Cell Biochem. 476, 3577\u20133590 (2021).","journal-title":"Mol. Cell Biochem."},{"key":"809_CR82","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41366-022-01082-7","volume":"46","author":"C Wei","year":"2022","unstructured":"Wei, C. et al. ChREBP-regulated lipogenesis is not required for the thermogenesis of brown adipose tissue. Int. J. Obes. 46, 1068\u20131075 (2022).","journal-title":"Int. J. Obes."},{"key":"809_CR83","doi-asserted-by":"publisher","first-page":"102218","DOI":"10.1016\/j.isci.2021.102218","volume":"24","author":"B Noblet","year":"2021","unstructured":"Noblet, B. et al. Dual regulation of TxNIP by ChREBP and FoxO1 in liver. iScience 24, 102218 (2021).","journal-title":"iScience"},{"key":"809_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/MED.0000000000000391","volume":"25","author":"L Thielen","year":"2018","unstructured":"Thielen, L. & Shalev, A. Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP. Curr. Opin. Endocrinol. Diabetes Obes. 25, 75\u201380 (2018).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"809_CR85","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1210\/en.2004-1378","volume":"146","author":"AH Minn","year":"2005","unstructured":"Minn, A. H., Hafele, C. & Shalev, A. Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces beta-cell apoptosis. Endocrinology 146, 2397\u20132405 (2005).","journal-title":"Endocrinology"},{"key":"809_CR86","doi-asserted-by":"publisher","first-page":"109488","DOI":"10.1016\/j.celrep.2021.109488","volume":"36","author":"AN Waldhart","year":"2021","unstructured":"Waldhart, A. N. et al. Excess dietary carbohydrate affects mitochondrial integrity as observed in brown adipose tissue. Cell Rep. 36, 109488 (2021).","journal-title":"Cell Rep."},{"key":"809_CR87","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cmet.2015.12.003","volume":"23","author":"S von Holstein-Rathlou","year":"2016","unstructured":"von Holstein-Rathlou, S. et al. FGF21 Mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab. 23, 335\u2013343 (2016).","journal-title":"Cell Metab."},{"key":"809_CR88","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cmet.2015.12.008","volume":"23","author":"S Talukdar","year":"2016","unstructured":"Talukdar, S. et al. FGF21 regulates sweet and alcohol preference. Cell Metab. 23, 344\u2013349 (2016).","journal-title":"Cell Metab."},{"key":"809_CR89","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.cmet.2019.01.004","volume":"29","author":"SA Kliewer","year":"2019","unstructured":"Kliewer, S. A. & Mangelsdorf, D. J. A dozen years of discovery: insights into the physiology and pharmacology of FGF21. Cell Metab. 29, 246\u2013253 (2019).","journal-title":"Cell Metab."},{"key":"809_CR90","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.celrep.2017.09.065","volume":"21","author":"A Iroz","year":"2017","unstructured":"Iroz, A. et al. A specific ChREBP and PPAR\u03b1 cross-talk is required for the glucose-mediated FGF21 response. Cell Rep. 21, 403\u2013416 (2017).","journal-title":"Cell Rep."},{"key":"809_CR91","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1016\/j.febslet.2009.07.053","volume":"583","author":"K Iizuka","year":"2009","unstructured":"Iizuka, K., Takeda, J. & Horikawa, Y. Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett. 583, 2882\u20132886 (2009).","journal-title":"FEBS Lett."},{"key":"809_CR92","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.molmet.2016.11.008","volume":"6","author":"FM Fisher","year":"2017","unstructured":"Fisher, F. M. et al. A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism. Mol. Metab. 6, 14\u201321 (2017).","journal-title":"Mol. Metab."},{"key":"809_CR93","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1097\/MCO.0b013e328361c4d1","volume":"16","author":"BA Neuschwander-Tetri","year":"2013","unstructured":"Neuschwander-Tetri, B. A. Carbohydrate intake and nonalcoholic fatty liver disease. Curr. Opin. Clin. Nutr. Metab. Care 16, 446\u2013452 (2013).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"809_CR94","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos, D. G., Vos, M. B. & Brunt, E. M. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu. Rev. Pathol. 5, 145\u2013171 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"809_CR95","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cmet.2017.12.016","volume":"27","author":"C Jang","year":"2018","unstructured":"Jang, C. et al. The small intestine converts dietary fructose into glucose and organic acids. Cell Metab. 27, 351\u2013361.e3 (2018).","journal-title":"Cell Metab."},{"key":"809_CR96","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1172\/JCI37385","volume":"119","author":"KL Stanhope","year":"2009","unstructured":"Stanhope, K. L. et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight\/obese humans. J. Clin. Invest. 119, 1322\u20131334 (2009).","journal-title":"J. Clin. Invest."},{"key":"809_CR97","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1210\/jc.2014-3678","volume":"100","author":"J-M Schwarz","year":"2015","unstructured":"Schwarz, J.-M. et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat. J. Clin. Endocrinol. Metab. 100, 2434\u20132442 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"809_CR98","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.metabol.2018.04.006","volume":"85","author":"A-R Oh","year":"2018","unstructured":"Oh, A.-R. et al. ChREBP deficiency leads to diarrhea-predominant irritable bowel syndrome. Metabolism 85, 286\u2013297 (2018).","journal-title":"Metabolism"},{"key":"809_CR99","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/nu10030340","volume":"10","author":"T Kato","year":"2018","unstructured":"Kato, T. et al. ChREBP-knockout mice show sucrose intolerance and fructose malabsorption. Nutrients 10, 340 (2018).","journal-title":"Nutrients"},{"key":"809_CR100","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1159\/000468811","volume":"46","author":"A Petersen","year":"1992","unstructured":"Petersen, A., Steinmann, B. & Gitzelmann, R. Essential fructosuria: increased levels of fructose 3-phosphate in erythrocytes. Enzyme 46, 319\u2013323 (1992).","journal-title":"Enzyme"},{"key":"809_CR101","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000175627","volume":"18","author":"B Steinmann","year":"1975","unstructured":"Steinmann, B., Baerlocher, K. & Gitzelmann, R. [Hereditary disorders of fructose metabolism. Loading tests with fructose, sorbitol and dihydroxyacetone]. Nutr. Metab. 18, 115\u2013132 (1975).","journal-title":"Nutr. Metab."},{"key":"809_CR102","doi-asserted-by":"publisher","first-page":"4320","DOI":"10.1073\/pnas.1119908109","volume":"109","author":"T Ishimoto","year":"2012","unstructured":"Ishimoto, T. et al. Opposing effects of fructokinase C and A isoforms on fructose-induced metabolic syndrome in mice. Proc. Natl Acad. Sci. USA 109, 4320\u20134325 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR103","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140848","volume":"6","author":"A Andres-Hernando","year":"2021","unstructured":"Andres-Hernando, A. et al. Vasopressin mediates fructose-induced metabolic syndrome by activating the V1b receptor. JCI Insight 6, e140848 (2021).","journal-title":"JCI Insight"},{"key":"809_CR104","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s42255-020-0222-9","volume":"2","author":"C Jang","year":"2020","unstructured":"Jang, C. et al. The small intestine shields the liver from fructose-induced steatosis. Nat. Metab. 2, 586\u2013593 (2020).","journal-title":"Nat. Metab."},{"key":"809_CR105","doi-asserted-by":"publisher","first-page":"4059","DOI":"10.1172\/JCI94585","volume":"127","author":"S Softic","year":"2017","unstructured":"Softic, S. et al. Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling. J. Clin. Invest. 127, 4059\u20134074 (2017).","journal-title":"J. Clin. Invest."},{"key":"809_CR106","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI89934","volume":"127","author":"D Zhang","year":"2017","unstructured":"Zhang, D. et al. Lipogenic transcription factor ChREBP mediates fructose-induced metabolic adaptations to prevent hepatotoxicity. J. Clin. Invest. 127, 2855\u20132867 (2017).","journal-title":"J. Clin. Invest."},{"key":"809_CR107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1210\/en.2012-1725","volume":"154","author":"DM Erion","year":"2013","unstructured":"Erion, D. M. et al. The role of the carbohydrate response element-binding protein in male fructose-fed rats. Endocrinology 154, 36\u201344 (2013).","journal-title":"Endocrinology"},{"key":"809_CR108","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.bbrc.2015.04.092","volume":"461","author":"W Wu","year":"2015","unstructured":"Wu, W. et al. Fat and carbohydrate in western diet contribute differently to hepatic lipid accumulation. Biochem. Biophys. Res. Commun. 461, 681\u2013686 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"809_CR109","doi-asserted-by":"publisher","first-page":"783393","DOI":"10.3389\/fphar.2021.783393","volume":"12","author":"S Yu","year":"2021","unstructured":"Yu, S., Li, C., Ji, G. & Zhang, L. The contribution of dietary fructose to non-alcoholic fatty liver disease. Front. Pharmacol. 12, 783393 (2021).","journal-title":"Front. Pharmacol."},{"key":"809_CR110","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1038\/s41586-020-2101-7","volume":"579","author":"S Zhao","year":"2020","unstructured":"Zhao, S. et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature 579, 586\u2013591 (2020).","journal-title":"Nature"},{"key":"809_CR111","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"P Puri","year":"2018","unstructured":"Puri, P. et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 67, 534\u2013548 (2018).","journal-title":"Hepatology"},{"key":"809_CR112","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hep.28709","volume":"65","author":"JP Arab","year":"2017","unstructured":"Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M. & Trauner, M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65, 350\u2013362 (2017).","journal-title":"Hepatology"},{"key":"809_CR113","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cmet.2012.04.004","volume":"15","author":"H-K Min","year":"2012","unstructured":"Min, H.-K. et al. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab. 15, 665\u2013674 (2012).","journal-title":"Cell Metab."},{"key":"809_CR114","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","volume":"152","author":"O Ch\u00e1vez-Talavera","year":"2017","unstructured":"Ch\u00e1vez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679\u20131694.e3 (2017).","journal-title":"Gastroenterology"},{"key":"809_CR115","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 394, 2184\u20132196 (2019).","journal-title":"Lancet"},{"key":"809_CR116","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.plipres.2012.11.002","volume":"52","author":"G Musso","year":"2013","unstructured":"Musso, G., Gambino, R. & Cassader, M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog. Lipid Res. 52, 175\u2013191 (2013).","journal-title":"Prog. Lipid Res."},{"key":"809_CR117","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1194\/jlr.M093229","volume":"60","author":"T Raselli","year":"2019","unstructured":"Raselli, T. et al. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. J. Lipid Res. 60, 1270 (2019).","journal-title":"J. Lipid Res."},{"key":"809_CR118","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hep4.1801","volume":"6","author":"CL Horn","year":"2022","unstructured":"Horn, C. L. et al. Role of cholesterol-associated steatohepatitis in the development of NASH. Hepatol. Commun. 6, 12\u201335 (2022).","journal-title":"Hepatol. Commun."},{"key":"809_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04361-y","volume":"9","author":"J Bricambert","year":"2018","unstructured":"Bricambert, J. et al. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity. Nat. Commun. 9, 2092 (2018).","journal-title":"Nat. Commun."},{"key":"809_CR120","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1002\/hep.30778","volume":"70","author":"JA Hoogerland","year":"2019","unstructured":"Hoogerland, J. A. et al. Glucose-6-phosphate regulates hepatic bile acid synthesis in mice. Hepatology 70, 2171\u20132184 (2019).","journal-title":"Hepatology"},{"key":"809_CR121","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.celrep.2015.08.068","volume":"13","author":"V Sarrazy","year":"2015","unstructured":"Sarrazy, V. et al. Maintenance of macrophage redox status by ChREBP limits inflammation and apoptosis and protects against advanced atherosclerotic lesion formation. Cell Rep. 13, 132\u2013144 (2015).","journal-title":"Cell Rep."},{"key":"809_CR122","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2010.10.024","volume":"55","author":"C Dubuquoy","year":"2011","unstructured":"Dubuquoy, C. et al. Distinct regulation of adiponutrin\/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes. J. Hepatol. 55, 145\u2013153 (2011).","journal-title":"J. Hepatol."},{"key":"809_CR123","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.120.003288","volume":"14","author":"DE Haslam","year":"2021","unstructured":"Haslam, D. E. et al. Sugar-sweetened beverage consumption may modify associations between genetic variants in the CHREBP (carbohydrate responsive element binding protein) locus and HDL-C (high-density lipoprotein cholesterol) and triglyceride concentrations. Circ. Genom. Precis. Med. 14, e003288 (2021).","journal-title":"Circ. Genom. Precis. Med."},{"key":"809_CR124","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2337\/dc13-2085","volume":"37","author":"GA Bray","year":"2014","unstructured":"Bray, G. A. & Popkin, B. M. Dietary sugar and body weight: have we reached a crisis in the epidemic of obesity and diabetes?: Health be damned! Pour on the sugar. Diabetes Care 37, 950\u2013956 (2014).","journal-title":"Diabetes Care"},{"key":"809_CR125","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"809_CR126","doi-asserted-by":"publisher","first-page":"15597","DOI":"10.1073\/pnas.0405238101","volume":"101","author":"S Ishii","year":"2004","unstructured":"Ishii, S., Iizuka, K., Miller, B. C. & Uyeda, K. Carbohydrate response element binding protein directly promotes lipogenic enzyme gene transcription. Proc. Natl Acad. Sci. USA 101, 15597\u201315602 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR127","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2337\/db12-0889","volume":"62","author":"R Kursawe","year":"2013","unstructured":"Kursawe, R. et al. Decreased transcription of ChREBP-\u03b1\/\u03b2 isoforms in abdominal subcutaneous adipose tissue of obese adolescents with prediabetes or early type 2 diabetes. Diabetes 62, 837\u2013844 (2013).","journal-title":"Diabetes"},{"key":"809_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2537","volume":"4","author":"L Eissing","year":"2013","unstructured":"Eissing, L. et al. De novo lipogenesis in human fat and liver is linked to ChREBP-\u03b2 and metabolic health. Nat. Commun. 4, 1528 (2013).","journal-title":"Nat. Commun."},{"key":"809_CR129","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrg.2016.56","volume":"17","author":"J Flannick","year":"2016","unstructured":"Flannick, J. & Florez, J. C. Type 2 diabetes: genetic data sharing to advance complex disease research. Nat. Rev. Genet. 17, 535\u2013549 (2016).","journal-title":"Nat. Rev. Genet."},{"key":"809_CR130","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003887","volume":"95","author":"MH Wehmeyer","year":"2016","unstructured":"Wehmeyer, M. H. et al. Nonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern. Medicine 95, e3887 (2016).","journal-title":"Medicine"},{"key":"809_CR131","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.clnu.2006.01.027","volume":"25","author":"H Cortez-Pinto","year":"2006","unstructured":"Cortez-Pinto, H. et al. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin. Nutr. 25, 816\u2013823 (2006).","journal-title":"Clin. Nutr."},{"key":"809_CR132","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/j.jhep.2012.07.003","volume":"57","author":"NJW de Wit","year":"2012","unstructured":"de Wit, N. J. W., Afman, L. A., Mensink, M. & M\u00fcller, M. Phenotyping the effect of diet on non-alcoholic fatty liver disease. J. Hepatol. 57, 1370\u20131373 (2012).","journal-title":"J. Hepatol."},{"key":"809_CR133","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/joim.12632","volume":"282","author":"M-R Taskinen","year":"2017","unstructured":"Taskinen, M.-R. et al. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. J. Intern. Med. 282, 187\u2013201 (2017).","journal-title":"J. Intern. Med."},{"key":"809_CR134","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrgastro.2010.191","volume":"8","author":"L Hebbard","year":"2011","unstructured":"Hebbard, L. & George, J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 8, 35\u201344 (2011).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"809_CR135","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","volume":"3","author":"L Parlati","year":"2021","unstructured":"Parlati, L., R\u00e9gnier, M., Guillou, H. & Postic, C. New targets for NAFLD. JHEP Rep. 3, 100346 (2021).","journal-title":"JHEP Rep."},{"key":"809_CR136","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1136\/gutjnl-2020-323323","volume":"71","author":"S Smati","year":"2022","unstructured":"Smati, S. et al. Integrative study of diet-induced mouse models of NAFLD identifies PPAR\u03b1 as a sexually dimorphic drug target. Gut 71, 807\u2013821 (2022).","journal-title":"Gut"},{"key":"809_CR137","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1007\/s00125-012-2703-1","volume":"55","author":"A Nakamura","year":"2012","unstructured":"Nakamura, A. et al. Protection from non-alcoholic steatohepatitis and liver tumourigenesis in high fat-fed insulin receptor substrate-1-knockout mice despite insulin resistance. Diabetologia 55, 3382\u20133391 (2012).","journal-title":"Diabetologia"},{"key":"809_CR138","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1210\/en.2009-0466","volume":"150","author":"J S\u00e1nchez","year":"2009","unstructured":"S\u00e1nchez, J., Palou, A. & Pic\u00f3, C. Response to carbohydrate and fat refeeding in the expression of genes involved in nutrient partitioning and metabolism: striking effects on fibroblast growth factor-21 induction. Endocrinology 150, 5341\u20135350 (2009).","journal-title":"Endocrinology"},{"key":"809_CR139","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1152\/physiolgenomics.00069.2012","volume":"44","author":"MJJ Ronis","year":"2012","unstructured":"Ronis, M. J. J. et al. Dietary fat source alters hepatic gene expression profile and determines the type of liver pathology in rats overfed via total enteral nutrition. Physiol. Genomics 44, 1073\u20131089 (2012).","journal-title":"Physiol. Genomics"},{"key":"809_CR140","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.1210\/en.2015-1210","volume":"156","author":"AM Nuotio-Antar","year":"2015","unstructured":"Nuotio-Antar, A. M. et al. FABP4-Cre mediated expression of constitutively active ChREBP protects against obesity, fatty liver, and insulin resistance. Endocrinology 156, 4020\u20134032 (2015).","journal-title":"Endocrinology"},{"key":"809_CR141","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.arr.2016.10.005","volume":"39","author":"MP Mattson","year":"2017","unstructured":"Mattson, M. P., Longo, V. D. & Harvie, M. Impact of intermittent fasting on health and disease processes. Ageing Res. Rev. 39, 46\u201358 (2017).","journal-title":"Ageing Res. Rev."},{"key":"809_CR142","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.cmet.2019.01.018","volume":"29","author":"F Madeo","year":"2019","unstructured":"Madeo, F., Carmona-Gutierrez, D., Hofer, S. J. & Kroemer, G. Caloric restriction mimetics against age-associated disease: targets, mechanisms, and therapeutic potential. Cell Metab. 29, 592\u2013610 (2019).","journal-title":"Cell Metab."},{"key":"809_CR143","doi-asserted-by":"publisher","first-page":"E358","DOI":"10.1152\/ajpendo.00027.2006","volume":"291","author":"K Iizuka","year":"2006","unstructured":"Iizuka, K., Miller, B. & Uyeda, K. Deficiency of carbohydrate-activated transcription factor ChREBP prevents obesity and improves plasma glucose control in leptin-deficient (ob\/ob) mice. Am. J. Physiol. Endocrinol. Metab. 291, E358\u2013E364 (2006).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"809_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/srep30111","volume":"6","author":"KE Kim","year":"2016","unstructured":"Kim, K. E. et al. Caloric restriction of db\/db mice reverts hepatic steatosis and body weight with divergent hepatic metabolism. Sci. Rep. 6, 30111 (2016).","journal-title":"Sci. Rep."},{"key":"809_CR145","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.celrep.2019.08.084","volume":"29","author":"D Yu","year":"2019","unstructured":"Yu, D. et al. Calorie-restriction-induced insulin sensitivity is mediated by adipose mTORC2 and not required for lifespan extension. Cell Rep. 29, 236\u2013248.e3 (2019).","journal-title":"Cell Rep."},{"key":"809_CR146","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev.nutr.27.061406.093618","volume":"27","author":"C Postic","year":"2007","unstructured":"Postic, C., Dentin, R., Denechaud, P.-D. & Girard, J. ChREBP, a transcriptional regulator of glucose and lipid metabolism. Annu. Rev. Nutr. 27, 179\u2013192 (2007).","journal-title":"Annu. Rev. Nutr."},{"key":"809_CR147","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1111\/dom.12910","volume":"19","author":"ZH Al-Oanzi","year":"2017","unstructured":"Al-Oanzi, Z. H. et al. Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes. Diabetes Obes. Metab. 19, 1078\u20131087 (2017).","journal-title":"Diabetes Obes. Metab."},{"key":"809_CR148","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1161\/ATVBAHA.120.315708","volume":"41","author":"D Hu","year":"2021","unstructured":"Hu, D. et al. New insight into metformin-induced cholesterol-lowering effect crosstalk between glucose and cholesterol homeostasis via ChREBP (carbohydrate-responsive element-binding protein)-mediated PCSK9 (proprotein convertase subtilisin\/kexin Type 9) regulation. Arterioscler. Thromb. Vasc. Biol. 41, e208\u2013e223 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"809_CR149","doi-asserted-by":"publisher","first-page":"E1699","DOI":"10.3390\/nu10111699","volume":"10","author":"K Iizuka","year":"2018","unstructured":"Iizuka, K., Takao, K., Kato, T., Horikawa, Y. & Takeda, J. ChREBP reciprocally regulates liver and plasma triacylglycerol levels in different manners. Nutrients 10, E1699 (2018).","journal-title":"Nutrients"},{"key":"809_CR150","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molmet.2014.09.008","volume":"4","author":"JR Dushay","year":"2015","unstructured":"Dushay, J. R. et al. Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol. Metab. 4, 51\u201357 (2015).","journal-title":"Mol. Metab."},{"key":"809_CR151","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.cmet.2007.05.002","volume":"5","author":"MK Badman","year":"2007","unstructured":"Badman, M. K. et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab. 5, 426\u2013437 (2007).","journal-title":"Cell Metab."},{"key":"809_CR152","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1210\/en.2013-1191","volume":"154","author":"JPG Camporez","year":"2013","unstructured":"Camporez, J. P. G. et al. Cellular mechanisms by which FGF21 improves insulin sensitivity in male mice. Endocrinology 154, 3099\u20133109 (2013).","journal-title":"Endocrinology"},{"key":"809_CR153","doi-asserted-by":"publisher","first-page":"250","DOI":"10.2337\/db08-0392","volume":"58","author":"J Xu","year":"2009","unstructured":"Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250\u2013259 (2009).","journal-title":"Diabetes"},{"key":"809_CR154","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cmet.2007.05.003","volume":"5","author":"T Inagaki","year":"2007","unstructured":"Inagaki, T. et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab. 5, 415\u2013425 (2007).","journal-title":"Cell Metab."},{"key":"809_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/srep27938","volume":"6","author":"J-G Park","year":"2016","unstructured":"Park, J.-G. et al. CREBH\u2013FGF21 axis improves hepatic steatosis by suppressing adipose tissue lipolysis. Sci. Rep. 6, 27938 (2016).","journal-title":"Sci. Rep."},{"key":"809_CR156","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1073\/pnas.1200797109","volume":"109","author":"W Wei","year":"2012","unstructured":"Wei, W. et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor \u03b3. Proc. Natl Acad. Sci. USA 109, 3143\u20133148 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"809_CR157","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/oby.22344","volume":"27","author":"ED Charles","year":"2019","unstructured":"Charles, E. D. et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity 27, 41\u201349 (2019).","journal-title":"Obesity"},{"key":"809_CR158","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","volume":"392","author":"A Sanyal","year":"2019","unstructured":"Sanyal, A. et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet 392, 2705\u20132717 (2019).","journal-title":"Lancet"},{"key":"809_CR159","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","volume":"27","author":"SA Harrison","year":"2021","unstructured":"Harrison, S. A. et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat. Med. 27, 1262\u20131271 (2021).","journal-title":"Nat. Med."},{"key":"809_CR160","doi-asserted-by":"publisher","first-page":"e57","DOI":"10.1210\/clinem\/dgab624","volume":"107","author":"DJ Rader","year":"2022","unstructured":"Rader, D. J. et al. LLF580, an FGF21 analog, reduces triglycerides and hepatic fat in obese adults with modest hypertriglyceridemia. J. Clin. Endocrinol. Metab. 107, e57\u2013e70 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"809_CR161","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.153740","volume":"8","author":"A Sargsyan","year":"2023","unstructured":"Sargsyan, A. et al. HGFAC is a ChREBP regulated hepatokine that enhances glucose and lipid homeostasis. JCI Insight 8, e153740 (2023).","journal-title":"JCI Insight"},{"key":"809_CR162","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2020.10.030","volume":"74","author":"O Kucukoglu","year":"2021","unstructured":"Kucukoglu, O., Sowa, J.-P., Mazzolini, G. D., Syn, W.-K. & Canbay, A. Hepatokines and adipokines in NASH-related hepatocellular carcinoma. J. Hepatol. 74, 442\u2013457 (2021).","journal-title":"J. Hepatol."},{"key":"809_CR163","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.jcmgh.2021.10.007","volume":"13","author":"J Ma","year":"2021","unstructured":"Ma, J. et al. A novel humanized model of NASH and its treatment with META4, a potent agonist of MET. Cell Mol. Gastroenterol. Hepatol. 13, 565\u2013582 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"809_CR164","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/hep.1840150103","volume":"15","author":"P Schirmacher","year":"1992","unstructured":"Schirmacher, P., Geerts, A., Pietrangelo, A., Dienes, H. P. & Rogler, C. E. Hepatocyte growth factor\/hepatopoietin A is expressed in fat-storing cells from rat liver but not myofibroblast-like cells derived from fat-storing cells. Hepatology 15, 5\u201311 (1992).","journal-title":"Hepatology"},{"key":"809_CR165","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/ijms22052754","volume":"22","author":"N Qayyum","year":"2021","unstructured":"Qayyum, N., Haseeb, M., Kim, M. S. & Choi, S. Role of thioredoxin-interacting protein in diseases and its therapeutic outlook. Int. J. Mol. Sci. 22, 2754 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"809_CR166","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.cmet.2020.07.002","volume":"32","author":"LA Thielen","year":"2020","unstructured":"Thielen, L. A. et al. Identification of an anti-diabetic, orally available small molecule that regulates TXNIP expression and glucagon action. Cell Metab. 32, 353\u2013365.e8 (2020).","journal-title":"Cell Metab."},{"key":"809_CR167","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28826-3","volume":"13","author":"G Xu","year":"2022","unstructured":"Xu, G. et al. Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes. Nat. Commun. 13, 1159 (2022).","journal-title":"Nat. Commun."},{"key":"809_CR168","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","volume":"24","author":"F Ovalle","year":"2018","unstructured":"Ovalle, F. et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat. Med. 24, 1108\u20131112 (2018).","journal-title":"Nat. Med."},{"key":"809_CR169","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1210\/ME.2015-1090","volume":"29","author":"X Li","year":"2015","unstructured":"Li, X. et al. New insight into metformin action: regulation of ChREBP and FOXO1 activities in endothelial cells. Mol. Endocrinol. 29, 1184\u20131194 (2015).","journal-title":"Mol. Endocrinol."},{"key":"809_CR170","doi-asserted-by":"publisher","first-page":"101196","DOI":"10.1016\/j.molmet.2021.101196","volume":"48","author":"JA Gutierrez","year":"2021","unstructured":"Gutierrez, J. A. et al. Pharmacologic inhibition of ketohexokinase prevents fructose-induced metabolic dysfunction. Mol. Metab. 48, 101196 (2021).","journal-title":"Mol. Metab."},{"key":"809_CR171","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.medj.2021.04.007","volume":"2","author":"DJ Kazierad","year":"2021","unstructured":"Kazierad, D. J. et al. Inhibition of ketohexokinase in adults with NAFLD reduces liver fat and inflammatory markers: a randomized phase 2 trial. Med 2, 800\u2013813.e3 (2021).","journal-title":"Med"},{"key":"809_CR172","doi-asserted-by":"publisher","first-page":"100217","DOI":"10.1016\/j.jhepr.2020.100217","volume":"3","author":"EL Shepherd","year":"2021","unstructured":"Shepherd, E. L. et al. Ketohexokinase inhibition improves NASH by reducing fructose-induced steatosis and fibrogenesis. JHEP Rep. 3, 100217 (2021).","journal-title":"JHEP Rep."},{"key":"809_CR173","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.11.019","author":"A-R Oh","year":"2022","unstructured":"Oh, A.-R. et al. Hepatocyte Kctd17 inhibition ameliorates glucose intolerance and hepatic steatosis caused by obesity-induced Chrebp stabilization. Gastroenterology https:\/\/doi.org\/10.1053\/j.gastro.2022.11.019 (2022).","journal-title":"Gastroenterology"},{"key":"809_CR174","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","volume":"13","author":"B Gross","year":"2017","unstructured":"Gross, B., Pawlak, M., Lefebvre, P. & Staels, B. PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat. Rev. Endocrinol. 13, 36\u201349 (2017).","journal-title":"Nat. Rev. Endocrinol."},{"key":"809_CR175","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","volume":"51","author":"AB Mayerson","year":"2002","unstructured":"Mayerson, A. B. et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51, 797\u2013802 (2002).","journal-title":"Diabetes"},{"key":"809_CR176","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","volume":"177","author":"G Musso","year":"2017","unstructured":"Musso, G., Cassader, M., Paschetta, E. & Gambino, R. Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis. JAMA Intern. Med. 177, 633\u2013640 (2017).","journal-title":"JAMA Intern. Med."},{"key":"809_CR177","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann, J. M. et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270, 12953\u201312956 (1995).","journal-title":"J. Biol. Chem."},{"key":"809_CR178","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa060326","volume":"355","author":"R Belfort","year":"2006","unstructured":"Belfort, R. et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355, 2297\u20132307 (2006).","journal-title":"N. Engl. J. Med."},{"key":"809_CR179","unstructured":"Medicines and Healthcare Products Regulatory Agency. Rosiglitazone: Recommended Withdrawal from Clinical Use https:\/\/www.gov.uk\/drug-safety-update\/rosiglitazone-recommended-withdrawal-from-clinical-use (2014)."},{"key":"809_CR180","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","volume":"24","author":"KS T\u00f8lb\u00f8l","year":"2018","unstructured":"T\u00f8lb\u00f8l, K. S. et al. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis. World J. Gastroenterol. 24, 179\u2013194 (2018).","journal-title":"World J. Gastroenterol."},{"key":"809_CR181","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong, M. J. et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387, 679\u2013690 (2016).","journal-title":"Lancet"},{"key":"809_CR182","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","volume":"50","author":"P Newsome","year":"2019","unstructured":"Newsome, P. et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity. Aliment. Pharmacol. Ther. 50, 193\u2013203 (2019).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"809_CR183","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.cmet.2020.02.014","volume":"31","author":"RE Gimeno","year":"2020","unstructured":"Gimeno, R. E., Briere, D. A. & Seeley, R. J. Leveraging the gut to treat metabolic disease. Cell Metab. 31, 679\u2013698 (2020).","journal-title":"Cell Metab."},{"key":"809_CR184","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller, T. D. et al. Glucagon-like peptide 1 (GLP-1). Mol. Metab. 30, 72\u2013130 (2019).","journal-title":"Mol. Metab."}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00809-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00809-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T09:54:43Z","timestamp":1684144483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-023-00809-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":184,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["809"],"URL":"https:\/\/doi.org\/10.1038\/s41574-023-00809-4","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"31 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}